Co-Diagnostics Q3 revenue $0.6M down from $2.5M; net loss $9.7M ($0.32/share)

Co-Diagnostics, Inc.

2024-Q3 EPS reported -$0.88 revenue$3,765,835

Q3 2024 revenue $0.6M ($0.4M grant + $0.2M product) vs $2.5M prior year, down 76%.
Net loss $9.7M ($0.32 per diluted share) vs $6.0M ($0.20) prior year; operating loss $10.2M.
Adjusted EBITDA loss $8.8M; cash and securities $37.7M as of Sept 30, 2024.
FDA 510(k) review ongoing for Co-Dx PCR platform; TB, respiratory, HPV multiplex tests in pipeline.
India oligonucleotide (Co-Primers) mfg facility inauguration expected early Dec 2024.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.